Roche: new data backs haemophilia treatment
(CercleFinance.com) - New data from phase III trials support Hemlibra's efficacy, safety and quality of life benefit in people with haemophilia A, Roche said on Tuesday.
Over 87% of the participants in the studies had no treated joint bleeds and over 92% of participants experienced no spontaneous bleeds from week 25.
Roche said that safety data from another study adds to the growing body of evidence supporting Hemlibra to "redefine" the standard of care for people with haemophilia.
According to the results from the first interim analysis of a phase IIIb study, including data from 88 patients, no cases of thrombotic microangiopathy or thrombotic events were reported, Roche said.
The results were presented at the International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Over 87% of the participants in the studies had no treated joint bleeds and over 92% of participants experienced no spontaneous bleeds from week 25.
Roche said that safety data from another study adds to the growing body of evidence supporting Hemlibra to "redefine" the standard of care for people with haemophilia.
According to the results from the first interim analysis of a phase IIIb study, including data from 88 patients, no cases of thrombotic microangiopathy or thrombotic events were reported, Roche said.
The results were presented at the International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.
Copyright (c) 2019 CercleFinance.com. All rights reserved.